USPTO Examiner SOROUSH LAYLA - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18405787EFFECTIVE ANTICANCER DRUG CANDIDATE OF DINUCLEAR PALLADIUM (II) BIS-DIHYDROZONE MALONYL COMPLEXJanuary 2024April 2024Allow300YesNo
18526686NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSDecember 2023July 2024Allow710YesNo
183787586'-(4-CHLOROPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'- CARBONITRILES AS ANTIMICROBIAL COMPOUNDSOctober 2023March 2024Allow511YesNo
18447620PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATIONAugust 2023December 2023Allow410YesNo
18189073NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSMarch 2023April 2024Allow1320YesNo
18177640SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATEMarch 2023August 2024Abandon1821NoNo
18171431ANALGESIC AND ANTIPRURITIC PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOFFebruary 2023November 2023Allow910YesNo
18170804TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAINFebruary 2023September 2024Abandon1910NoNo
18160874PHARMACEUTICAL COMPOSITIONS FOR TREATING PAINJanuary 2023November 2023Allow1011YesNo
18096794MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERSJanuary 2023April 2024Allow1521YesNo
18153870NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSJanuary 2023August 2023Allow710YesNo
17982909COMPOSITIONS FOR TOPICAL TREATMENT OF RADIATION DERMATITISNovember 2022March 2024Allow1741YesNo
17998098TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTSNovember 2022December 2023Abandon1310NoNo
17976660TOPICAL OPHTHALMOLOGICAL COMPOSITIONSOctober 2022January 2024Allow1421YesNo
17961943STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDEOctober 2022December 2023Allow1421YesNo
17929569TOPICAL FORMULATIONS CONTAINING MTOR INHIBITORSSeptember 2022October 2023Allow1321YesNo
17901284STABLE FORMULATIONS COMPRISING THIOTEPASeptember 2022March 2024Allow1821YesNo
17822756STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDEAugust 2022August 2023Allow1221YesNo
17881191COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSEAugust 2022September 2023Allow1310NoNo
17879838ORAL PHARMACEUTICAL SOLUTION OF CLOPIDOGRELAugust 2022November 2023Abandon1521NoNo
17861054COMPOSITIONS AND METHODS COMPRISING SANSHOOL AS LIP INTERACTING COMPONENTSJuly 2022September 2023Allow1422YesNo
17808234SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONJune 2022June 2023Allow1200NoNo
17836560BUPROPION AS A MODULATOR OF DRUG ACTIVITYJune 2022December 2022Allow610YesNo
17745378Aqueous Suspensions of TMC278May 2022May 2024Allow2420YesNo
17716505AMLODIPINE FORMULATIONSApril 2022May 2024Allow2600YesNo
17712524STABLE PHARMACEUTICAL FORMULATIONApril 2022January 2023Allow1020YesNo
17704168TOPICAL FORMULATION FOR A JAK INHIBITORMarch 2022October 2022Allow720YesNo
17557626COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDSDecember 2021September 2022Allow911YesNo
17535830COMPOSITIONS FOR USE IN SURGERYNovember 2021May 2024Abandon3011NoNo
17492377TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASESOctober 2021September 2024Abandon3621NoNo
17467207OIL-IN-WATER TYPE DERMATOLOGICAL COMPOSITION FOR EXTERNAL USESeptember 2021June 2024Allow3320NoNo
17403800Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or CaffeineAugust 2021January 2024Abandon2910NoNo
17396951COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERSAugust 2021December 2023Abandon2801NoNo
17391808ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USEAugust 2021April 2024Abandon3211NoNo
17366668COMPOSITION AND METHOD FOR TREATING INFECTIONSJuly 2021October 2023Abandon2741NoNo
17358966TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSISJune 2021May 2024Abandon3520NoNo
17352336Anthocyanin and Quercetin Based Formulations for Improved Respiratory HealthJune 2021December 2023Abandon3010NoNo
17344314METHODS OF TREATING A PATIENT HAVING PARKINSON'S DISEASEJune 2021May 2023Abandon2321YesNo
17344415STABLE ORGANIC CANNABINOID OIL BLEND FORMULATIONSJune 2021October 2022Abandon1601NoNo
17326922Parenteral Formulations of Dopamine AgonistsMay 2021February 2024Abandon3310NoNo
17293941USE OF BULLEYACONITINE AMay 2021March 2024Allow3400YesNo
17314281Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsMay 2021February 2022Allow911YesNo
17314274TOPICAL REGIONAL NEURO-AFFECTIVE THERAPYMay 2021October 2023Abandon2910NoNo
17245085BIOAVAILABLE MINERALS FOR THE MITIGATION OF CORONA VIRUSES (COVID 19), MANUFACTURING METHOD AND A TREATMENT METHODApril 2021January 2024Abandon3201NoNo
17239007PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATIONApril 2021August 2023Allow2741YesNo
17217311BUPROPION AS A MODULATOR OF DRUG ACTIVITYMarch 2021February 2022Allow1011YesNo
17249917METHODS FOR TREATING ACNEMarch 2021December 2023Abandon3301NoNo
17194016AMLODIPINE FORMULATIONSMarch 2021February 2022Allow1121YesNo
17194146TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASESMarch 2021September 2021Allow611YesNo
17184353Therapeutic Terpene FormulationsFebruary 2021December 2023Abandon3301NoNo
17178156ANTIVIRAL COMPOUNDSFebruary 2021March 2024Allow3731YesNo
17158464METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPIONJanuary 2021April 2022Abandon1520NoNo
17158392NON-CRYSTALLIZING CANNABIDIOL BLENDSJanuary 2021January 2023Allow2421YesNo
17156671ANTIBIOTIC GEL FORMULATION AND METHODS OF PREPARING THE ANTIBIOTIC GEL FORMULATIONJanuary 2021November 2023Abandon3301NoNo
17108679Parenteral FormulationDecember 2020November 2022Abandon2300NoNo
15734068SYNERGIC PHARMACEUTICAL COMPOSITION OF THE ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAINDecember 2020September 2022Allow2121YesNo
17100758METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTSNovember 2020June 2023Abandon3132YesNo
169506544,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONSNovember 2020July 2023Allow3211YesNo
17095391METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINENovember 2020July 2023Abandon3210NoNo
17094233PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUMNovember 2020April 2023Allow2910YesNo
17088871OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERSNovember 2020July 2023Abandon3310NoNo
17080360nAChR-alpha7 Agonists and nAChR-alpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD)October 2020April 2024Abandon4220YesNo
17072923TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANESOctober 2020July 2023Allow3321NoNo
17064759USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASEOctober 2020May 2023Allow3211YesNo
17045339Method of administering a MedicationOctober 2020May 2024Abandon4401NoNo
17039769ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERSSeptember 2020December 2023Abandon3821NoNo
17043521SULFONAMIDE-CONTAINING 4-(N-METHYL) AMINOPIPERIDINE MYRICETIN DERIVATIVES, PREPARATION METHOD AND APPLICATIONSeptember 2020March 2024Allow4211YesNo
16982281TOPICAL COMPOSITIONSeptember 2020October 2022Allow2521YesNo
17000995VAP-1 INHIBITORS FOR TREATING PAINAugust 2020May 2024Abandon4421NoNo
16999368HYDROPHILIC GEL FOR TOPICAL DELIVERY OF 5-AMINOLEVULINIC ACIDAugust 2020September 2023Allow3721YesNo
16947809PROCESS FOR INCREASING THE STABILITY OF A COMPOSITION COMPRISING POLYUNSATURATED OMEGA-3 FATTY ACIDSAugust 2020June 2023Allow3431YesNo
16990259ABUSE-DETERRENT COMPOSITIONSAugust 2020June 2024Abandon4640YesYes
16940102COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDSJuly 2020November 2022Allow2840YesNo
16927678AMLODIPINE FORMULATIONSJuly 2020December 2020Allow510NoNo
16927664AMLODIPINE FORMULATIONSJuly 2020December 2020Allow510NoNo
16899952TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOFJune 2020September 2021Allow1521YesNo
16898249TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAINJune 2020February 2024Allow4420YesNo
16896385SYSTEM AND METHOD FOR APPLYING TREATMENT TO A TREATMENT ZONEJune 2020August 2024Abandon5031YesNo
16856363Topical Analgesic CompositionsApril 2020June 2024Allow5031YesNo
16855907DERMAL COMPOSITIONSApril 2020April 2023Allow3611YesNo
16853380AMLODIPINE FORMULATIONSApril 2020October 2020Allow601YesNo
16840345Therapeutic Calcium Phosphate Particles in Use for Aesthetic or Cosmetic Medicine, and Methods of Manufacture and UseApril 2020January 2023Abandon3310NoNo
16824496METHODS OF TREATMENT WITH DEUTERATED CFTR POTENTIATORSMarch 2020October 2023Abandon4311NoNo
16637777NASAL DECONGESTANT COMPOSITIONS COMPRISING DEXPANTHENOL AND SODIUM HYALURONATEFebruary 2020July 2023Abandon4220NoNo
16774270CANNABIONID AND CANNABIS-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACTJanuary 2020November 2022Abandon3401NoNo
16631205Photodynamic Therapy Method for Skin DisordersJanuary 2020November 2022Abandon3411NoNo
16696110AR+ BREAST CANCER TREATMENT METHODSNovember 2019June 2023Allow4221YesNo
16673549PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USENovember 2019September 2022Allow3420YesNo
16608783TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAINOctober 2019June 2024Abandon5641YesNo
16605785METHODS FOR DIAGNOSING AND TREATING CACHEXIAOctober 2019March 2023Abandon4121NoNo
16593677ANIMAL FEED COMPOSITIONS OF ABSCISIC ACIDOctober 2019September 2023Abandon4750NoNo
16593190TOPICAL REGIONAL NEURO-AFFECTIVE THERAPYOctober 2019July 2021Abandon2210NoNo
16592340SHIKIMATE ANALOGUES AND METHODS OF USEOctober 2019February 2022Abandon2821NoNo
16586690TRANSPORE DELIVERY OF DRUGS AND USES THEREOFSeptember 2019January 2023Abandon4011NoNo
16578002Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or CaffeineSeptember 2019March 2023Allow4211YesNo
16547120OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERSAugust 2019March 2021Abandon1820NoNo
16485544NANOEMULSION COMPRISING IMIDAZOQUINOLINE-BASED MATERIAL AND USE THEREOFAugust 2019June 2023Abandon4631NoNo
16537596PROCESS FOR PRODUCING A NANO-CBD MICROEMULSION SYSTEMAugust 2019September 2022Allow3811YesNo
16522853Method Of Manufacturing Fine Particles Suitable For Orally Disintegrating Pharmaceutical Dosage FormsJuly 2019July 2020Abandon1220NoNo
16448335IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERYJune 2019May 2023Allow4731YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, LAYLA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
52
Examiner Affirmed
27
(51.9%)
Examiner Reversed
25
(48.1%)
Reversal Percentile
69.0%
Higher than average

What This Means

With a 48.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
184
Allowed After Appeal Filing
59
(32.1%)
Not Allowed After Appeal Filing
125
(67.9%)
Filing Benefit Percentile
46.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SOROUSH, LAYLA - Prosecution Strategy Guide

Executive Summary

Examiner SOROUSH, LAYLA works in Art Unit 1627 and has examined 754 patent applications in our dataset. With an allowance rate of 33.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner SOROUSH, LAYLA's allowance rate of 33.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SOROUSH, LAYLA receive 2.55 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SOROUSH, LAYLA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +55.9% benefit to allowance rate for applications examined by SOROUSH, LAYLA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.2% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 89.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 61.2% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 48.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 46.6% are granted (fully or in part). This grant rate is in the 53% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.